NanoGroup to Build High-Value Revenue Pipeline For Polish Biotechs
Biotech, M&A
Warsaw-listed NanoGroup reveals acquisition strategy focused on young, underfunded biotech firms in Poland, aiming to build a diversified project portfolio with long-term revenue-share potential and faster paths to partnerships.
NanoGroup, a publicly traded Polish biotech company, has unveiled a bold growth strategy focused on acquiring early-stage, privately held biotech startups in Poland. The company’s leadership, led by CEO Przemysław Mazurek, shared this direction during a recent press briefing, underlining its goal to create a robust and predictable revenue pipeline based on diversified assets and commercial partnerships.
“Our strategy is to acquire young biotech firms in Poland with a strong scientific foundation but often limited financial resources,” Mazurek explained. “We’re targeting smaller, non-listed companies with promising project portfolios that have a real chance of securing near-term partnerships. This approach allows us to build a diversified pipeline and, over time, establish steady revenue through shared licensing and development agreements.”
Subscribe to Startup Digest to stay ahead with the latest news, investments, and must-attend events.
This acquisition-based growth model is not just theoretical. NanoGroup recently made its first move by acquiring Auxilius Pharma, which it expects to bring to partnering readiness within the next two to three years. While Mazurek declined to disclose the names of other potential targets, he confirmed that several are under active consideration.
Building a Biotech Powerhouse through Consolidation
NanoGroup’s updated strategy, formally adopted last week for the 2026–2028 timeframe, calls for:
Signing at least two major partnering agreements
Growing its portfolio to a minimum of 10 active development projects
Reaching the Top 3 largest biotech groups in Poland by market cap by 2028
The company aims to expand across multiple therapeutic verticals and regulatory pathways—including human pharmaceuticals, medical devices, and veterinary products. This diversity, Mazurek noted, is essential for managing risk and increasing the likelihood of successful partnerships and long-term returns.
The recent transaction with FF Venture Capital (FFVC) further strengthens NanoGroup’s position. FFVC subscribed to 5,953 preferred shares in NanoGroup worth PLN 7.5 million (approx. €1.7 million), with the capital earmarked for acquiring shares in Auxilius Pharma. This financing provides critical support for accelerating NanoGroup’s entry into partnership-ready biotech assets.
“When developing this strategy, we validated our direction with financial institutions to confirm the market attractiveness and value potential for investors and partners alike,” Mazurek added.
Spotlight on NanOX and Upcoming Milestones
One of NanoGroup’s flagship projects is NanOX, a proprietary platform with strong commercialization prospects. According to the company, a key certification pathway for NanOX is expected to be initiated as early as January 2026, opening the door for regulatory progress and potential partnerships. The Q4 2026 to Q1 2027 window is seen as the optimal time to secure a licensing or co-development agreement.
“All of this is geared toward one overarching goal: to build the most predictable and profit-generating biotech group in the region,” Mazurek said in closing.
Strategic Implications for Poland’s Biotech Landscape
NanoGroup’s acquisition-focused strategy signals a shift in the Polish biotech ecosystem, where many early-stage startups struggle with limited funding and fragmented support. By consolidating scientifically credible yet undercapitalized biotech firms under a single umbrella, NanoGroup hopes to unlock value through scale, centralized development, and strategic deal-making.
This approach not only promises returns for NanoGroup and its investors but also enhances the broader innovation landscape in Poland by bringing visibility and growth opportunities to young, overlooked biotech startups.
Founded in 2017 and listed on the Warsaw Stock Exchange (GPW), NanoGroup focuses on developing innovative therapies and medical technologies across biotechnology, pharmaceuticals, and regenerative medicine. By combining scientific excellence with commercialization expertise, the company is positioning itself as a regional leader in biotech innovation and value creation.
